Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

The addition of a dermocosmetic cleanser and moisturizer also lessened the adverse events commonly associated with retinoid use.

Adjunctive Dermocosmetic Therapy Reduces Sensitivity and Improves Quality of Life for Patients with Acne

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

A recent study evaluated the efficacy of low-energy delicate pulsed light photomodulation for treating sensitive skin, showing significant improvements in symptoms and erythema.

Low-Energy Delicate Pulsed Light Therapy Shows Promise for Treating Sensitive Skin

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Mitragotri's work bridges advanced drug development and skin care for tailored treatments.

CAGE Bio Advances Skin Disease Treatment

According to a systemic review, both topical and oral antifungal therapies are insufficient for managing the disease.

Limited Evidence Supporting the Efficacy of Antifungals for Atopic Dermatitis

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Jennifer Fisher, MMSc, PA-C, is a board-certified dermatology physician assistant and medical writer in Connecticut.

CD19 CAR T-cell therapy may modulate immune dysregulation in underlying diseases such as psoriasis.

 Psoriasis Resolution in a Patient Treated With CD19 CAR T-Cell Therapy for Refractory DLBCL

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Today, Quoin Pharmaceuticals announced additional positive interim data from its ongoing, open-label study evaluating QRX003 for the treatment of Netherton Syndrome.

Positive improvements were observed using the Investigator’s Global Assessment (IGA), Worst Itch Numeric Rating Scale (WINRS), and Modified Ichthyosis Area Severity Index (M-IASI).

Study CL-QRX003-002 is a randomized, double-blinded, vehicle-controlled study testing the QRX003 topical lotion versus a placebo in patients 14 years and older. The product was applied twice daily for 12 weeks. Before and after photographs were also taken and published on 

At baseline, IGA was considered to be moderate with a WINRS score of 7 and a M-IASI score of 18. At the midpoint of the trial, disease severity improved to mild with a 4 on both the WINRS and the M-IASI. After 12 weeks, final results indicated a WINRS score of 2 and an M-IASI score of 3, resulting in an IGA of “almost clear.” Additionally, Patient Satisfaction Scoring was extremely positive with no reported adverse reactions.

“We are very excited to announce continued positive results from our ongoing Netherton Syndrome clinical studies. With the availability of photographic evidence that clearly demonstrates the profound change in skin appearance for this subject in our open-label study, we believe we are continuing to develop a growing body of evidence of the potential efficacy of QRX003 in Netherton Syndrome,” Michael Myers, PhD, CEO of Quoin Pharmaceuticals, said in a statement. “The marked improvement demonstrated across all measured endpoints is highly encouraging. Furthermore, and importantly, the patient satisfaction scores with QRX003 continue to be very positive, with no safety concerns observed.”

The study is being conducted under an open U.S. Investigational New Drug (IND) application, which was first approved by the US Food and Drug Administration (FDA) in 

This includes a whole-body trial, led by Amy Paller, MD, at Northwestern University, which aims to generate real-world data by administering QRX003 to a broader body surface area than in previous studies.

“[We] anticipate that clinical data from this study will become a key component of the data package we are assembling to support a New Drug Application (NDA) filing for QRX003 as potentially the first approved treatment for Netherton Syndrome,” Myers noted. “2025 is already off to an exciting start for Quoin and we look forward to providing additional updates throughout the year.”

Netherton Syndrome is a severe genetic skin condition caused by mutations in the SPINK5 gene, leading to excessive skin shedding and compromised skin barrier function. Current treatment options are limited and primarily focus on symptomatic relief.

QRX003 is designed to address the underlying pathology of Netherton Syndrome by inhibiting kallikreins, serine proteases that contribute to the excessive skin shedding characteristic of the disease. If successful, QRX003 could become the first FDA-approved treatment for Netherton Syndrome, offering new hope to patients and their families.

1. Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study. News Release. Globe Newswire. January 6, 2025. Accessed January 6, 2025. 

https://www.globenewswire.com/news-release/2025/01/06/3004620/0/en/Quoin-Pharmaceuticals-Announces-Additional-Positive-Interim-Data-from-Ongoing-Open-Label-Netherton-Syndrome-Clinical-Study.html

2. Quoin Pharmaceuticals announces FDA clearance to initiate new QRX003 Netherton Syndrome clinical study. News release. Globe Newswire. December 19, 2024. Accessed January 6, 2025. 

https://www.globenewswire.com/news-release/2024/12/19/2999779/0/en/Quoin-Pharmaceuticals-Announces-FDA-Clearance-to-Initiate-New-QRX003-Netherton-Syndrome-Clinical-Study.html

Quoin Pharmaceuticals has reported promising interim results from an open-label study of QRX003 for Netherton Syndrome, showing significant improvements in disease severity and patient satisfaction without adverse reactions. The study, involving patients aged 14 and older, demonstrated marked improvements in Investigator’s Global Assessment, Worst Itch Numeric Rating Scale, and Modified Ichthyosis Area Severity Index scores over 12 weeks. Conducted under an FDA-approved IND, the trial aims to support a New Drug Application for QRX003, potentially the first approved treatment for this severe genetic skin condition.

The results showed promising improvements in all endpoints with high patient satisfaction and no safety concerns.

Quoin Pharmaceuticals’ Announces Positive Interim QRX003 Data for Netherton Syndrome 

 has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025.

Using these responses, we have compiled a list of dermatological meetings taking place this year.

Interested in sharing what conferences you are interested in or planning to attend this year? 

2025

The compilation of dermatological meetings for 2025 is based on reader responses about anticipated conferences. Dermatology professionals have shared their plans and interests regarding upcoming events. This list serves as a resource for those in the field to identify key gatherings in the dermatology community. Readers are encouraged to contribute their own conference interests by contacting the editorial team. This engagement helps to ensure a comprehensive overview of significant dermatological meetings, fostering a collaborative and informed professional community.

Dermatology Times asked our readers to share what conferences they are looking forward to in 2025.

Dermatology Conferences and Meetings Calendar: 2025

"Atopic dermatitis (AD) remains a challenging condition to manage effectively, and despite advances in treatment, there is a persistent issue of therapeutic inertia in the field. This inertia, characterized by the failure to escalate treatment when patients do not meet their therapeutic targets, continues to undermine patient outcomes. The 

 has highlighted this issue in the real-world, showing that many patients with moderate-to-severe AD remain undertreated, leading to inadequate disease control and reduced quality of life," wrote Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine in New Haven, Connecticut, and 

recent review of new atopic dermatitis treatment targets.

The chronic physical symptoms of AD such as itchy and painful skin are often associated with affecting patients’ quality of sleep, sexual and social interactions, and work productivity. Due to the mental and physical effects of AD combined with dissatisfaction with current treatment regimens, more effective therapies are needed. 

Answer the poll below to learn more about recently published atopic dermatitis treatment recommendations.

Therapeutic inertia in atopic dermatitis (AD) management remains a significant barrier to effective treatment, as many patients with moderate-to-severe AD are undertreated, leading to poor disease control and diminished quality of life. The TARGET-DERM registry study underscores this issue, revealing that failure to escalate treatment when necessary is prevalent. AD's chronic symptoms, including itchy and painful skin, adversely impact sleep, social interactions, and work productivity. The combination of these physical and mental effects, along with dissatisfaction with current treatments, underscores the need for more effective therapeutic options.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

POLL: When Do You Escalate AD Treatment if Treatment Targets are Not Achieved?

The upcoming year is poised to bring significant advancements in dermatologic treatments, with 3 highly anticipated Prescription Drug User Fee Act (PDUFA) dates on the horizon. These therapies address pressing unmet needs in dermatology and promise to enhance patient care.

First, dupilumab (Dupixent) has the potential to become the first targeted therapy for chronic spontaneous urticaria in over a decade. Backed by strong data from the LIBERTY-CUPID clinical trials, Dupixent offers hope for patients struggling with uncontrolled itching and hives.

Next, prademagenezamikeracel (pz-cel) may revolutionize care for patients with recessive dystrophic epidermolysis bullosa, a rare and debilitating condition. The FDA's acceptance of Abeona Therapeutics’ resubmitted Biologics License Application puts this innovative gene therapy one step closer to addressing unmet needs in wound healing and pain management.

Finally, roflumilast foam 0.3% (Zoryve) offers a steroid-free, easy-to-apply option for treating scalp and body psoriasis. Results from the ARRECTOR phase 3 trial highlight its potential to clear plaques and relieve symptoms in hair-bearing and other hard-to-treat areas.

We want to hear from you. Which of these PDUFA dates are you most excited about, and why? Cast your vote in our poll below and share your thoughts with the 

Dupilumab (Dupixent; Sanofi) for chronic spontaneous urticaria

Pz-cel (prademagenezamikeracel) (Abeona Therapeutics) for recessive dystrophic epidermolysis bullosa

Roflumilast foam 0.3% (Zoryve; Arcutis Biotherapeutics) for scalp and body psoriasis

Want to share more of your insights and perspectives with us? Email our team at 

Dupixent (dupilumab) sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (CSU). News release. Regeneron. November 15, 2024. Accessed January 3, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic

Abeona Therapeutics announces FDA accepts and grants Priority Review for pz-cel biologics license application (BLA). News release. Abeona Therapeutics. November 27, 2023. Accessed January 3, 2025. 

https://investors.abeonatherapeutics.com/press-releases/detail/268/abeona-therapeutics-announces-fda-accepts-and-grants

Arcutis submits supplemental new drug application for ZORYVE (roflumilast) foam to the FDA for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over. News release. Arcutis Biotherapeutics, Inc. July 23, 2024. Accessed January 3, 2025. 

https://www.arcutis.com/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-foam-to-the-fda-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over/

Significant advancements in dermatologic treatments are anticipated with three upcoming Prescription Drug User Fee Act (PDUFA) dates. Dupilumab (Dupixent) could become the first targeted therapy for chronic spontaneous urticaria in over a decade, offering hope for patients with uncontrolled symptoms. Prademagenezamikeracel (pz-cel) may revolutionize care for recessive dystrophic epidermolysis bullosa, addressing unmet needs in wound healing and pain management. Roflumilast foam 0.3% (Zoryve) provides a steroid-free option for treating scalp and body psoriasis, showing promise in clearing plaques and relieving symptoms.

Share your insights and anticipation with us.

Jennifer Fisher, MMSc, PA-C

Articles

Latest Updated Articles